Publications

Availability and Utilization of Clinical Genomic Sequencing globally
  • Phillips KA, Douglas MP, Marshall DA. Use of Clinical Genomic Sequencing Expands but More Data on Implementation Are Needed. JAMA. 2020;324(20):2029-2030.

  • Phillips KA, Douglas MP, Wordsworth S, Buchanan J, Marshall DA. Availability and Funding of Clinical Genomic Sequencing Globally. BMJ Global Health. 2021;6:e004415.

 
Theme Section - Methods for Moving Evaluation of Precision Medicine into Practice and Policy - Value in Health
  • Phillips KA. Introduction to Themed Papers: Methods for Moving Evaluation of Precision Medicine into Practice and Policy. Value Health. 2020;23(5):527-528.

  • Deverka PA, Douglas MP, Phillips KA. Use of Real World Evidence in U.S. Payer Coverage Decision-making for NGS-based Tests: Challenges, Opportunities, and Potential Solutions. Value Health. 2020;23(5):540-550.

  • Marshall DA, Grazziotin Lago L, Regier DA, Wordsworth S, Buchanan J, Phillips KA, Ijzerman M. Using Simulation and Constraint Optimization Modeling to Address Challenges in Economic Evaluation of Precision Medicine. Value Health. 2020;23(5):566-573.

  • Mackay Z, Dukhovny D, Parad RB, Phillips KA, Beggs AH, Green R, Christensen KA. Methods for Identifying Health Care Attributable to Unexpected Genomic Results. Value Health. 2020;23(5):559-565.

  • Trosman JR, Douglas MP, Liang S, Weldon CB, Kurian AW, Kelley RK, Phillips KA. Insights from a Temporal Assessment of Increases in U.S. Private Payer Coverage of Tumor Sequencing from 2015 to 2019. Value Health. 2020;23(5):551-558.

 
Theme Section - Assessing the Value of Next Generation Sequencing - Value in Health
  • Phillips KA, Deverka PA, Marshall DA, Wordsworth S, Regier DA, Christensen KD, Buchanan J. Methodological Challenges and Solutions for Assessing Economic Value of Next Generation Sequencing Tests. Value Health. 2018; 21(9):1033-1042.

  • Wordsworth S, Doble B, Payne K, Buchanan J, Marshall DA, McCabe C, Regier DA. Using ‘big’ data in the cost-effectiveness analysis of genomic-based diagnostic tests: challenges and potential solutions. Value Health. 2018; 21(9):1048-1053.

  • Reiger DA, Weymann D, Buchanan J, Marshall DA, Wordsworth S. Valuation of Health and Non-health Benefits from Next Generation Sequencing: Approaches, Challenges, and Solutions. Value Health 2018; 21(9):1043-1047.

  • Christensen KD, Phillips KA, Green RC, Dukhovny D. Cost Analyses of Genomic Sequencing – Lessons Learned from the MedSeq Project. Value Health. 2018; 21(9):1054-1061.

  • Trosman JR, Weldon CB, Gradishar WJ, Benson AB III, Cristofanilli M, Kurian AW, Ford JM, Balch A, Watkins J, Phillips KA. From the Past to the Present: Insurer Coverage Frameworks for Next-Generation Tumor Sequencing. Value Health. 2018; 21(9):1062- 1068.

 
Theme Issue - Precision Medicine - Health Affairs
  • Ginsburg GS, Phillips KA. Precision Medicine: From Science to Value. Health Affairs. 2018;37(5): 694-701.

  • Phillips KA, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Affairs. 2018;37(5): 710-716.

 
Theme Section - Value to Decision Makers of Evaluations of Personalized / Precision Medicine: Applications to Other Emerging Technologies - Value in Health
  • Phillips KA. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction. Value Health. 2017;20(1):30-31.

  • Phillips KA, Douglas MP, Trosman JR, Marshall DA. “What goes around comes around”: lessons learned from economic evaluations of personalized medicine applied to digital medicine. Value Health. 2017;20(1):32- 38.

  • Marshall DA, Gonzalez JM, MacDonald KV, Johnson FR. Estimating preferences for complex health technologies: lessons learned and implications for personalized medicine. Value Health. 2017;20(1):17-24.

  • Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips KA. Decision making on medical innovations in a changing health care environment: insights from accountable care organizations and payers on personalized medicine and other technologies. Value Health. 2017;20(1):25-31.

  • Rosenman MB, Decker B, Levy KD, Holmes AM, Pratt VM, Eadon MT. Lessons learned when introducing pharmacogenomic panel testing into clinical practice. Value Health. 2017;20(1):39-44.